Recent developments in active tumor targeted multifunctional nanoparticles for combination chemotherapy in cancer treatment and imaging

Journal of Biomedical Nanotechnology

Volumn 11, Issue 11, 2015, Pages 1859-1898

  Glasgow, Micah D K ^a   Chougule, Mahavir B ^a,b  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Cancer; Combination Chemotherapy; Drug Delivery; Multi Drug Resistance; Multifunctional Nanoparticles; Nanoparticles; Targeted Nanoparticles

Indexed keywords

CHEMOTHERAPY; DISEASES; DRUG DELIVERY; DRUG DOSAGE; DRUG INTERACTIONS; DRUG THERAPY; ONCOLOGY; TUMORS;

CANCER; COMBINATION CHEMOTHERAPY; MULTI-FUNCTIONAL NANOPARTICLES; MULTIDRUG RESISTANCE; TARGETED NANOPARTICLE;

NANOPARTICLES;

ANTINEOPLASTIC AGENT; APTAMER; DENDRIMER; DRUG ANTIBODY; LIPOSOME; MOLECULAR THERAPY AGENT; NANOCARRIER; NANOCONJUGATE; NANOPARTICLE; PEPTIDE; POLYGLACTIN; SILICON DIOXIDE; POLYMER;

CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; HUMAN; IMAGING AND DISPLAY; MICELLE; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; MULTIMODAL IMAGING; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERIZATION; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; DIAGNOSTIC IMAGING; DRUG SCREENING; MEDICAL RESEARCH; MOUSE; NANOMEDICINE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CELL LINE, TUMOR; DENDRIMERS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MICE; NANOMEDICINE; NANOPARTICLES; POLYMERS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84956577740     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2145     Document Type: Review

References (293)

1. A. Bangham and R. Horne, Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J. Mol. Biol. 8, 660 (1964).
2. L. Zhang, A. F. Radovic-Moreno, F. Alexis, F. X. Gu, P. A. Basto, V. Bagalkot, S. Jon, R. S. Langer, and O. C. Farokhzad, Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. Chem. Med. Chem. 2, 1268 (2007).
3. M. Davis, Z. Chen, and D. Shin, Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771 (2008).
4. V. Wagner, A. Dullaart, A. K. Bock, and A. Zweck, The emerging nanomedicine landscape. Nat. Biotechnol. 24, 1211 (2006).
5. D. W. Northfelt, B. J. Dezube, J. A. Thommes, B. J. Miller, M. A. Fischl, A. Friedman-Kien, L. D. Kaplan, C. Du Mond, R. D. Mamelok, and D. H. Henry, Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. J. Clin. Oncol. 16, 2445 (1998).
6. M. Harries, P. Ellis, and P. Harper, Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J. Clin. Oncol. 23, 7768 (2005).
7. L. Zhang, F. X. Gu, J. M. Chan, A. Z. Wang, R. S. Langer, and O. C. Farokhzad, Nanoparticles in medicine: Therapeutic applications and developments. Clin. Pharmacol. Ther. 83, 761 (2008).
8. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751 (2007).
9. Y. Matsumura and H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387 (1986).
10. F. Greco and M. J. Vicent, Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliver. Rev. 61, 1203 (2009).
11. J. T. Dong, Prevalent mutations in prostate cancer. J. Cell. Biochem. 97, 433 (2006).
12. D. Hanahan and R. A. Weinberg, The Hallmarks of cancer. Cell 100, 57 (2000).
13. M. Suggitt and M. C. Bibby, 50 years of preclinical anticancer drug screening: Empirical to target-driven approaches. Clin. Cancer Res. 11, 971 (2005).
14. G. F. Ismael, D. D. Rosa, M. S. Mano, and A. Awada, Novel cytotoxic drugs: Old challenges, new solutions. Cancer Treat. Rev. 34, 81 (2008).
15. S. Aryal, C. M. Hu, and L. Zhang, Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small 6, 1442 (2010).
16. N. Kolishetti, S. Dhar, P. Valencia, L. Lin, R. Karnik, S. Lippard, R. Langer, and O. Farokhzad, Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. P. Natl. Acad. Sci. USA. 107, 17939 (2010).
17. J. S. James and G. Dubs, FDA approves new kind of lymphoma treatment. Food and Drug Administration. AIDS Treat. News 2 (1997).
18. J. Albanell and J. Baselga, Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drug Today 35, 931 (1999).
19. L. H. Liu, K. J. Xu, H. Y. Wang, P. K. J. Tan, W. M. Fan, S. S. Venkatraman, L. J. Li, and Y. Y. Yang, Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat. Nan-otechnol. 4, 457 (2009).
20. L. H. Liu, K. Guo, J. Lu, S. S. Venkatraman, D. Luo, K. C. Ng, E. A. Ling, S. Moochhala, and Y. Y. Yang, Biologically active core/shell nanopaticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Bioma-terials 10, 1509 (2008).
21. H. Krakovicova, T. Etrych, and K. Ulbrich, HPMA-based polymer conjugates with drug combination. Eur. J. Pharm. Sci. 37, 405 (2009).
22. R. K. Tekade, T. Dutta, V. Gajbhiye, and N. K. Jain, Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. J. Microencapsul. 26, 287 (2009).
23. S. Ganta and M. Amiji, Coadministration of paclitaxel and cur-cumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. 6, 928 (2009).
24. A. Chen, M. Zhang, D. Wei, D. Stueber, O. Taratula, T. Minko, and H. He, Co-delivery of doxorubicin and Bcl-2 siRNA by meso-porous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 5, 2673 (2009).
25. L. D. Mayer and A. S. Janoff, Optimizing combination chemotherapy by controlling drug ratios. Mol. Interv. 7, 216 (2007).
26. Y. Wang, S. Gao, W. H. Ye, H. S. Yoon, and Y. Y. Yang, Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater. 5, 791 (2006).
27. M. Saad, O. B. Garbuzenko, and T. Minko, Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine-UK. 3, 761 (2008).
28. P. Debbage and W. Jaschke, Molecular imaging with nanoparticles: Giant roles for dwarf actors. Histochem. Cell Biol. 130, 845 (2008).
29. V. Bagalkot, L. Zhang, E. Levy-Nissenbaum, S. Jon, P. W. Kantoff, R. Langer, and O. C. Farokhzad, Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 7, 3065 (2007).
30. J.-H. Park, G. Maltzahn, L. Zhang, M. Schwartz, E. Ruoslahti, S. Bhatia, and M. Sailor, Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv. Mater. 20, 1630 (2008).
31. N. Nasongkla, E. Bey, J. Ren, H. Ai, C. Khemtong, J. S. Guthi, S. F. Chin, A. D. Sherry, D. A. Boothman, and J. Gao, Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 6, 2427 (2006).
32. J. R. McCarthy and R. Weissleder, Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv. Drug Deliver. Rev. 60, 1241 (2008).
33. W. R. Sanhai, J. H. Sakamoto, R. Canady, and M. Ferrari, Seven challenges for nanomedicine. Nat. Nanotechnol. 3, 242 (2008).
34. K. Riehemann, S. W. Schneider, T. A. Luger, B. Godin, M. Ferrari, and H. Fuchs, Nanomedicine-challenge and perspectives. Angew. Chem. Int. Ed. Engl. 48, 872 (2009).
35. Y. Sheng, L. D. Liao, N. V. Thakor, and M. C. Tan, Nanoparticles for molecular imaging. J. Biomed. Nanotechnol. 10, 2641 (2014).
36. B. Dubertret, P. Skourides, D. J. Norris, V. Noireaux, A. H. Brivanlou, and A. Libchaber, In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 298, 1759
37. H. T. Shi, J. F. Wei, L. Qiang, X. Chen, and X. W. Meng, Fluorescent carbon dots for bioimaging and biosensing applications. J. Biomed. Nanotechnol. 10, 2677 (2014).
38. N. Chanda, V. Kattumuri, R. Shukla, A. Zambre, K. Katti, A. Upendran, R. R. Kulkarni, P. Kan, G. M. Fent, S. W. Casteel, C. J. Smith, E. Boote, J. D. Robertson, C. Cutler, J. R. Lever, K. V. Katti, and R. Kannan, Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. P. Natl. Acad. Sci. USA. 107, 8760 (2010).
39. L. B. Nie, F. H. Liu, P. Ma, and X. Y. Xiao, Applications of gold nanoparticles in optical biosensors. J. Biomed. Nanotechnol. 10, 2700 (2014).
40. A. De La Zerda, C. Zavaleta, S. Keren, S. Vaithilingam, S. Bodapati, Z. Liu, J. Levi, B. R. Smith, T.-J. Ma, O. Oralkan, Z. Cheng, X. Chen, H. Dai, B. T. Khuri-Yakub, and S. S. Gambhir, Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat. Nanotechnol. 3, 557 (2008).
41. J. Ramon-Azcon, S. Ahadian, R. Obregon, H. Shiku, M. Ramalingam, and T. Matsue, Applications of carbon nanotubes in stem cell research. J. Biomed. Nanotechnol. 10, 2539 (2014).
42. A. Shapira, Y. D. Livney, H. J. Broxterman, and Y. G. Assaraf, Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resist. Update 14, 150 (2011).
43. G. N. Chiu, M. Y. Wong, L. U. Ling, I. M. Shaikh, K. B. Tan, A. Chaudhury, and B. J. Tan, Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: Implications on pharmacokinetics and drug toxicities. Curr. Drug Metab. 10, 861 (2009).
44. M. M. Gottesman, Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615 (2002).
45. M. Koval, K. Preiter, C. Adles, P. D. Stahl, and T. H. Steinberg, Size of IgG-opsonized particles determines macrophage response during internalization. Exp. Cell Res. 242, 265 (1998).
46. J. Huwyler, A. Cerletti, G. Fricker, A. N. Eberle, and J. Drewe, Bypassing of P-glycoprotein using immunoliposomes. J. Drug Target. 10, 73 (2002).
47. J. Rejman, V. Oberle, I. S. Zuhorn, and D. Hoekstra, Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem. J. 377, 159 (2004).
48. M. Bebawy and M. Chetty, Gender differences in p-glycoprotein expression and function: Effects on drug disposition and outcome. Curr. Drug Metab. 10, 322 (2009).
49. D. M. Bradshaw and R. J. Arceci, Clinical relevance of transmem-brane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol. 16, 3674 (1998).
50. M. Hennessy and J. P. Spiers, A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol. Rev. 55, 1 (2007).
51. R. P. Andres, S. Datta, D. B. Janes, C. P. Kubiak, and R. Reifenberger, The design, fabrication and electronic properties of self-assembled molecular nanostructures, Handbook of Nanos-tructured Materials and Nanotechnology, edited by H. S. Nalwa, American Press, San Diego, CA (2000), Vol. 3, pp. 179-231.
52. B. G. Sumpter, D. W. Noid, M. D. Barnes, and J. U. Otaigbe, Encyclopedia of Nanoscience and Nanotechnology, edited by H. S. Nalwa, American Scientific Publisher, Los Angeles (2004/2011), Vol. 8, pp. 873-903.
53. W. Zhou, Encyclopedia of Nanoscience and Nanotechnology, edited by H. S. Nalwa, American Scientific Publisher, Los Angeles (2004/2011), Vol. 10, pp. 149-160.
54. T. Imae, K. Funayama, Y. Nakanishi, and K. Yoshii, Encyclopedia of Nanoscience and Nanotechnology, edited by H. S. Nalwa, American Scientific Publisher, Los Angeles (2004/2011), Vol. 3, pp. 685-702.
55. P. Walde, Encyclopedia of Nanoscience and Nanotechnology, edited by H. S. Nalwa, American Scientific Publisher, Los Angeles (2004/2011), Vol. 9, pp. 43-80.
56. H. S. Nalwa, A special issue on revCieowpsyrinighnat:noAmmedeicriincea, drug delivery and vaccine development. J. Biomed. Nanotechnol. 10, 1635 (2014).
57. H. S. Nalwa, A special issue on reviews in biomedical applications of nanomaterials, tissue engineering, stem cells, bioimaging, and toxicity. J. Biomed. Nanotechnol. 10, 2421 (2014).
58. A. D. Bangham, M. M. Standish, and J. C. Watkins, Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13, 238 (1965).
59. W. F. Bayne, L. D. Mayer, and C. E. Swenson, Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. J. Pharm. Sci. 98, 2540 (2009).
60. T. Aas, A. L. Borresen, S. Geisler, B. Smith-Sorensen, H. Johnsen, J. E. Varhaug, L. A. Akslen, and P. E. Lonning, Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2, 811 (1996).
61. A. Persidis, Cancer multidrug resistance. Nat. Biotechnol. 17, 94 (1999).
62. A. Anand and M. Huberman, Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 76, 916 (1995).
63. P. Parhi, C. Mohanty, and S. K. Sahoo, Nanotechnology-based combinational drug delivery: An emerging approach for cancer therapy. Drug Discov. Today 17, 1044 (2012).
64. S. Wu and R. K. Singh, Resistance to chemotherapy and molecu-larly targeted therapies: Rationale for combination therapy in malignant melanoma. Curr. Mol. Med. 11, 553 (2011).
65. Y. Chen, X. Zhu, X. Zhang, B. Liu, and L. Huang, Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 18, 1650 (2010).
66. N. Li, H. Fu, Y. Tie, Z. Hu, W. Kong, Y. Wu, and X. Zheng, miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 275, 44 (2009).
67. F. de Nigris, M. L. Balestrieri, and C. Napoli, Targeting c-Myc, Ras and IGF cascade to treat cancer and vascular disorders. Cell Cycle 5, 1621 (2006).
68. M. J. Halaby and D. Q. Yang, p53 translational control: A new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. Genetics 395, 1 (2007).
69. A. Grothey, Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer. Semin. Oncol. 33, S41 (2006).
70. S. H. Kang, H. J. Cho, G. Shim, S. Lee, S. H. Kim, H. G. Choi, C. W. Kim, and Y. K. Oh, Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy. Pharm. Res. 28, 3069 (2011).
71. G. Shim, S. E. Han, Y. H. Yu, S. Lee, H. Y. Lee, K. Kim, I. C. Kwon, T. G. Park, Y. B. Kim, Y. S. Choi, C. W. Kim, and Y. K. Oh, Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J. Control Release 155, 60 (2011).
72. D. Grossman, P. J. Kim, J. S. Schechner, and D. C. Altieri, Inhibition of melanoma tumor growth in vivo by survivin targeting. P. Natl. Acad. Sci. USA. 98, 635 (2001).
73. M. Zhang, O. B. Garbuzenko, K. R. Reuhl, L. Rodriguez-Rodriguez, and T. Minko, Two-in-one: Combined targeted chemo and gene therapy for tumor suppression and prevention of metas-tases. Nanomedicine-UK. 7, 185 (2012).
74. R. R. Sawant, O. S. Vaze, K. Rockwell, and V. P. Torchilin, Palmitoyl ascorbate-modified liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel co-delivery. Eur. J. Pharm. Biopharm. 75, 321 (2010).
75. R. R. Sawant, O. S. Vaze, K. Rockwell, and V. P. Torchilin, Palmitoyl ascorbate-modified liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel co-delivery. Eur. J. Pharm. Biopharm. 75, 321 (2010).
76. K. Unsal-Kacmaz, S. Ragunathan, E. Rosfjord, S. Dann, E. Upeslacis, M. Grillo, R. Hernandez, F. Mack, and A. Klippel, The interaction of PKN3 with RhoC promotes malignant growth. Mol. Oncol. 6, 284 (2012).
77. M. Aleku, P. Schulz, O. Keil, A. Santel, U. Schaeper, B. Dieckhoff, O. Janke, J. Endruschat, B. Durieux, N. Roder, K. Loffler, C. Lange, M. Fechtner, K. Mopert, G. Fisch, S. Dames, W. Arnold, K. Jochims, K. Giese, B. Wiedenmann, A. Scholz, and J. Kaufmann, Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 68, 9788 (2008).
78. D. Strumberg, B. Schultheis, U. Traugott, C. Vank, A. Santel, O. Keil, K. Giese, J. Kaufmann, and J. Drevs, First-in-human phase I study of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3) in patients with advanced solid tumors. J. Clin. Oncol. 29, 1 (2011).
79. W. Dai, W. Jin, J. Zhang, X. Wang, J. Wang, X. Zhang, Y. Wan, and Q. Zhang, Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes. Pharm. Res. 29, 2902 (2012).
80. J. Hu, L. J. Chen, L. Liu, X. Chen, P. L. Chen, G. Yang, W. L. Hou, M. H. Tang, F. Zhang, X. H. Wang, X. Zhao, and Y. Q. Wei, Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity. Exp. Mol. Med. 40, 617 (2008).
81. P. E. Huber, M. Bischof, J. Jenne, S. Heiland, P. Peschke, R. Saffrich, H. J. Grone, J. Debus, K. E. Lipson, and A. Abdollahi, Trimodal cancer treatment: Beneficial effects of combined antian-giogenesis, radiation, and chemotherapy. Cancer Res. 65, 3643 (2005).
82. Y. Maitani, H. Saito, Y. Seishi, Y. Iwase, T. Yamauchi, K. Higashiyama, and T. Sugino, A combination of liposomal suni-tinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse. J. Drug Target. 20, 873 (2012).
83. A. Sochanik, I. Mitrus, R. Smolarczyk, T. Cichon, M. Snietura, M. Czaja, and S. Szala, Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemothera-peutic agent. Arch. Immunol. Ther. Ex. 58, 235 (2010).
84. Y. F. Zhang, J. C. Wang, D. Y. Bian, X. Zhang, and Q. Zhang, Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies. Eur. J. Pharm. Biopharm. 74, 467 (2010).
85. D. Zucker, A. V. Andriyanov, A. Steiner, U. Raviv, and Y. Barenholz, Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: Relating structure and pharmacokinetics to therapeutic efficacy. J. Control Release. 160, 281 (2012).
86. M. Y. Wong and G. N. Chiu, Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine-UK. 7, 834 (2011).
87. E. J. Feldman, J. E. Kolitz, J. M. Trang, B. D. Liboiron, C. E. Swenson, M. T. Chiarella, L. D. Mayer, A. C. Louie, and J. E. Lancet, Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine: Daunorubicin, in patients with advanced leukemia. Leukemia Res. 36, 1283 (2012).
88. W. S. Lim, P. G. Tardi, N. Dos Santos, X. Xie, M. Fan, B. D. Liboiron, X. Huang, T. O. Harasym, D. Bermudes, and L. D. Mayer, Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine: Daunorubicin formulation, in bone marrow xenografts. Leukemia Res. 34, 1214 (2010).
89. K. Riviere, H. M. Kieler-Ferguson, K. Jerger, and F. C. Szoka, Jr., Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan. J. Control Release 153, 288 (2011).
90. P. Tardi, S. Johnstone, N. Harasym, S. Xie, T. Harasym, N. Zisman, P. Harvie, D. Bermudes, and L. Mayer, In vivo maintenance of synergistic cytarabine: Daunorubicin ratios greatly enhances therapeutic efficacy. Leukemia Res. 33, 129 (2009).
91. Y. T. Ko, C. Falcao, and V. P. Torchilin, Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol. Pharm. 6, 971 (2009).
92. E. Bajelan, A. Haeri, A. M. Vali, S. N. Ostad, and S. Dadashzadeh, Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. J. Pharm. Pharm. Sci. 15, 568 (2012).
93. P. Avci, S. S. Erdem, and M. R. Hamblin, Photodynamic therapy: One step ahead with self-assembled nanoparticles. J. Biomed. Nanotechnol. 10, 1937 (2014).
94. G. C. Bolfarini, M. P. Siqueira-Moura, G. J. Demets, P. C. Morais, and A. C. Tedesco, In vitro evaluation of combined hyperther-mia and photodynamic effects using magnetoliposomes loaded with cucurbituril zinc phthalocyanine complex on melanoma. J. Photoch. Photobio. B. 115, 1 (2012).
95. R. G. Strickley, Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21, 201 (2004).
96. M. Yokoyama, G. S. Kwon, T. Okano, Y. Sakurai, T. Seto, and K. Kataoka, Preparation of micelle-forming polymer-drug conjugates. Bioconjugate Chem. 3, 295 (1992).
97. A. Kabanov, S. Vinogradov, Y. Suzdaltseva, and A. Vyu, Water-soluble block polycations as carriers for oligonucleotide delivery. Bioconjugate Chem. 6, 639 (1995).
98. C. M. Hu and L. Zhang, Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 83, 1104 (2012).
99. V. P. Torchilin, Micellar nanocarriers: Pharmaceutical perspectives. Pharm. Res. 24, 1 (2007).
100. Y. Hu, Z. Jiang, R. Chen, W. Wu, and X. Jiang, Degradation and degradation-induced re-assembly of PVP-PCL micelles. Biomacro-molecules 11, 481 (2010).
101. I. Orienti, G. Zuccari, A. Fini, A. M. Rabasco, R Carosio, L. Raffaghello, and P. G. Montaldo, Modified doxorubicin for improved encapsulation in PVA polymeric micelles. Drug Deliv. 12, 15 (2005).
102. D. Mishra, H. C. Kang, and Y. H. Bae, Reconstitutable charged polymeric (PLGA)(2)-b-PEI micelles for gene therapeutics delivery. Biomaterials 32, 3845 (2011).
103. E. Blanco, C. W. Kessinger, B. D. Sumer, and J. Gao, Multifunctional micellar nanomedicine for cancer therapy. Exp. Biol. Med. (Maywood) 234, 123 (2009).
104. T. Chandran, U. Katragadda, Q. Teng, and C. Tan, Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG). Int. J. Pharm. 392, 170 (2010).
105. V. P. Torchilin, Structure and design of polymeric surfactant-based drug delivery systems. J. Control Release 73, 137 (2001).
106. A. V. Kabanov, E. V. Batrakova, and V. Y Alakhov, Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control Release 82, 189 (2002).
107. A. S. Mikhail and C. Allen, Poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: Synthesis, characterization, and the influence of the drug on micelle morphology. Biomacromolecules 11, 1273 (2010).
108. Y. Kakizawa, S. Furukawa, and K. Kataoka, Block copolymer-coated calcium phosphate nanoparticles sensing intracellular environment for oligodeoxynucleotide and siRNA delivery. J. Control Release 97, 345 (2004).
109. A. Lavasanifar, J. Samuel, and G. S. Kwon, Poly(ethylene oxide)-block-poly(l-amino acid) micelles for drug delivery. Adv. Drug Deliver. Rev. 54, 169 (2002).
110. P. Chytil, T. Etrych, C. Konak, M. Sirova, T. Mrkvan, J. Boucek, B. Rihova, and K. Ulbrich, New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting. J. Control Release 127, 121 (2008).
111. Z. Jia, L. Wong, T. P. Davis, and V. Bulmus, One-pot conversion of RAFT-generated multifunctional block copolymers of HPMA to doxorubicin conjugated acid-and reductant-sensitive crosslinked micelles. Biomacromolecules 9, 3106 (2008).
112. S. S. Chandran, A. Nan, D. M. Rosen, H. Ghandehari, and S. R. Denmeade, A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Mol. Cancer Ther 6, 2928 (2007).
113. B. S. Lele and J. C. Leroux, Synthesis and micellar characterization of novel amphiphilic A-B-A triblock copolymers of N-(2-Hydroxypropyl)methacrylamide or N-Vinyl-2-pyrrolidone with Poly(s-caprolactone). Macromolecules 35, 6714 (2002).
114. D. Neradovic, M. J. van Steenbergen, L. Vansteelant, Y. J. Meijer, C. F. van Nostrum, and W. E. Hennink, Degradation mechanism and kinetics of thermosensitive polyacrylamides containing lactic acid side chains. Macromolecules 36, 7491 (2003).
115. O. Soga, C. F. van Nostrum, M. Fens, C. J. Rijcken, R. M. Schiffelers, G. Storm, and W. E. Hennink, Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J. Control Release 103, 341 (2005).
116. M. Talelli, C. J. Rijcken, C. F. van Nostrum, G. Storm, and W. E. Hennink, Micelles based on HPMA copolymers. Adv. Drug Deliver. Rev. 62, 231 (2010).
117. S. G. Krimmer, H. Pan, J. Liu, J. Yang, and J. Kopecek, Synthesis and characterization of poly(epsilon-caprolactone)-block-poly[N-(2-hydroxypropyl)methacrylamide] micelles for drug delivery. Macromol. Biosci. 11, 1041 (2011).
118. A. L. Lee, Y. Wang, H. Y. Cheng, S. Pervaiz, and Y. Y. Yang, The co-delivery of paclitaxel and herceptin using cationic micellar nanoparticles. Biomaterials 30, 919 (2009).
119. C. Oerlemans, W. Bult, M. Bos, G. Storm, J. F. Nijsen, and W. E. Hennink, Polymeric micelles in anticancer therapy: Targeting, imaging and triggered release. Pharm. Res. 27, 2569 (2010).
120. F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. Le Breton, and V. Preat, PLGA-based nanoparticles: An overview of biomedical applications. J. Control Release 161, 505 (2012).
121. H. Zhu, H. Chen, X. Zeng, Z. Wang, X. Zhang, Y. Wu, Y. Gao, J. Zhang, K. Liu, R. Liu, L. Cai, L. Mei, and S.-S. Feng, Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance. Biomaterials 35, 2391 (2014).
122. H. Wang, Y. Zhao, Y. Wu, Y.-l. Hu, K. Nan, G. Nie, and H. Chen, Enhanced anti-tumor efficacy by co-delivery of doxoru-bicin and paclitaxel with amphiphilic methoxy PEG-PLGA copoly-mer nanoparticles. Biomaterials 32, 8281 (2011).
123. Y. Lu, Y. Yang, A. Sellinger, M. Lu, J. Huang, H. Fan, R. Haddad, G. Lopez, A. Burns, D. Sasaki, J. Shelnutt, and C. Brinker, Self-assembly of mesoscopically ordered chromatic polydiacety-lene/silica nanocomposites. Nature 410, 913 (2001).
124. A. Roy, M. S. Singh, P. Upadhyay, and S. Bhaskar, Nanoparti-cle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model. Int. J. Pharm. 445, 171 (2013).
125. X. Ma, Y. Zhao, K. W. Ng, and Y. Zhao, Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery. Chem-Eur. J. 19, 15593 (2013).
126. H. Meng, W. Mai, H. Zhang, M. Xue, T. Xia, S. Lin, X. Wang, Y. Zhao, Z. Ji, J. Zink, and A. Nel, Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS 7, 994 (2013).
127. N. J. Hao, L. F. Li, and F. Q. Tang, Shape-mediated biological effects of mesoporous silica nanoparticles. J. Biomed. Nanotechnol. 10, 2508 (2014).
128. L. L. Li, T. L. Liu, C. H. Fu, H. Y. Liu, L. F. Tan, and X. W. Meng, Multifunctional silica-based nanocomposites for cancer nanothera-nostics. J. Biomed. Nanotechnol. 10, 1784 (2014).
129. J. Fang, H. Nakamura, and H. Maeda, The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliver. Rev. 63, 136 (2011).
130. H. Sun, F. Meng, A. A. Dias, M. Hendriks, J. Feijen, and Z. Zhong, Alpha-amino acid containing degradable polymers as functional biomaterials: Rational design, synthetic pathway, and biomedical applications. Biomacromolecules 12, 1937 (2011).
131. R. De Souza, P. Zahedi, C. J. Allen, and M. Piquette-Miller, Polymeric drug delivery systems for localized cancer chemotherapy. Drug Deliver. 17, 365 (2010).
132. A. C. Couffin-Hoarau, A. M. Aubertin, M. Boustta, S. Schmidt, J. A. Fehrentz, J. Martinez, and M. Vert, Peptide-poly(L-lysine cit-ramide) conjugates and their in vitro anti-HIV behavior. Biomacro-molecules 10, 865 (2009).
133. D. Yang, S. Van, J. Liu, J. Wang, X. Jiang, Y. Wang, and L. Yu, Physicochemical properties and biocompatibility of a polymer-paclitaxel conjugate for cancer treatment. Intl. J. Nanomed. 6, 2557 (2011).
134. J. M. Metselaar, P. Bruin, L. W. de Boer, T. de Vringer, C. Snel, C. Oussoren, M. H. Wauben, D. J. Crommelin, G. Storm, and W. E. Hennink, A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjugate Chem. 14, 1156 (2003).
135. A. D. Baldwin and K. L. Kiick, Polysaccharide-modified synthetic polymeric biomaterials. Biopolymers 94, 128 (2010).
136. J. D. Kemp, T. Cardillo, B. C. Stewart, E. Kehrberg, G. Weiner, B. Hedlund, and P. W. Naumann, Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxam-ine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Res. 55, 3817 (1995).
137. D. S. Pisal, M. P. Kosloski, and S. V. Balu-Iyer, Delivery of therapeutic proteins. J. Pharm. Sci. 99, 2557 (2010).
138. A. V. Yurkovetskiy and R. J. Fram, XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Adv. Drug Deliver. Rev. 61, 1193 (2009).
139. S. D. Chipman, F. B. Oldham, G. Pezzoni, and J. W. Singer, Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Intl. J. Nanomed. 1, 375 (2006).
140. T. M. Beer, C. Ryan, J. Alumkal, C. W. Ryan, J. Sun, and K. M. Eilers, A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Colloq. Inse. 21, 433 (2010).
141. M. Mita, A. Mita, J. Sarantopoulos, C. H. Takimoto, E. K. Rowinsky, O. Romero, P. Angiuli, C. Allievi, A. Eisenfeld, and C. F. Verschraegen, Phase I study of paclitaxel poliglumex adminis tered weekly for patients with advanced solid malignancies. Cancer Chemoth. Pharm. 64, 287 (2009).
142. P. Sabbatini, M. W. Sill, D. O'Malley, L. Adler, A. A. Secord, and S. Gynecologic Oncology Group, A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study. Gynecol. Oncol. 111, 455 (2008).
143. M. E. O'Brien, M. A. Socinski, A. Y. Popovich, I. N. Bondarenko, A. Tomova, B. T. Bilynsky, Y. S. Hotko, V. L. Ganul, I. Y. Kostinsky, A. J. Eisenfeld, L. Sandalic, F. B. Oldham, B. Bandstra, A. B. Sandler, and J. W. Singer, Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J. Thorac. Oncol. 3, 728 (2008).
144. M. Man and H. Rugo, Paclitaxel poliglumex. Cell Therapeu-tics/Chugai Pharmaceutical. IDrugs. 8, 739 (2005).
145. P. Sapra, H. Zhao, M. Mehlig, J. Malaby, P. Kraft, C. Longley, L. M. Greenberger, and I. D. Horak, Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin. Cancer Res. 14, 1888 (2008).
146. M. Pechar, K. Ulbrich, V. Subr, L. W. Seymour, and E. H. Schacht, Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin. Bioconjugate Chem. 11, 131 (2000).
147. T. Etrych, P. Chytil, T. Mrkvan, M. Sirova, B. Rihova, and K. Ulbrich, Conjugates of doxorubicin with graft HPMA copoly-mers for passive tumor targeting. J. Control Release 132, 184 (2008).
148. T. Etrych, J. Strohalm, P. Chytil, P. Cernoch, L. Starovoytova, M. Pechar, and K. Ulbrich, Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting. Eur. J. Pharm. Sci. 42, 527 (2011).
149. T. Etrych, L. Kovar, J. Strohalm, P. Chytil, B. Rihova, and K. Ulbrich, Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy. J. Control Release. 154, 241 (2011).
150. J. Yang, K. Luo, H. Pan, P. Kopeckova, and J. Kopecek, Synthesis of biodegradable multiblock copolymers by click coupling of RAFT-generated heterotelechelicpolyhpma conjugates. React. Funct. Polym. 71, 294 (2011).
151. K. Luo, J. Yang, P. Kopeckova, and J. Kopecek, Biodegradable multiblock poly[N-(2-hydroxypropyl)methacrylamide] via reversible addition-fragmentation chain transfer polymerization and click chemistry. Macromolecules 44, 2481 (2011).
152. E. Wang, H. Xiong, D. Zhou, Z. Xie, Y. Huang, X. Jing, and X. Sun, Co-delivery of oxaliplatin and demethylcantharidin via a polymer-drug conjugate. Macromol. Biosci. 14, 588 (2014).
153. T. L. Kaneshiro and Z. R. Lu, Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials 30, 5660 (2009).
154. D. A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder, and P. Smith, A new class of polymers: Starburst-dendritic macromolecules. Polym J. 17, 117 (1985).
155. D. A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder, and P. Smith, Dendritic macromolecules: Synthesis of starburst dendrimers. Macromolecules 19, 2466 (1986).
156. R. Esfand and D. A. Tomalia, Poly(amidoamine) (PAMAM) den-drimers: From biomimicry to drug delivery and biomedical applications. Drug Discover. Today 6, 427 (2001).
157. S. Svenson and D. A. Tomalia, Dendrimers in biomedical applications-reflections on the field. Adv. Drug Deliver. Rev. 57, 2106 (2005).
158. G. Thiagarajan, A. Ray, A. Malugin, and H. Ghandehari, PAMAM-camptothecin conjugate inhibits proliferation and induces nuclear fragmentation in colorectal carcinoma cells. Pharm. Res. 27, 2307 (2010).
159. N. Vijayalakshmi, A. Ray, A. Malugin, and H. Ghandehari, Carboxyl-terminated PAMAM-SN38 conjugates: Synthesis, characterization, and in vitro evaluation. Bioconjugate Chem. 21, 1804 (2010).
160. I. J. Majoros, C. R. Williams, A. Becker, and J. R. Baker, Jr., Methotrexate delivery via folate targeted dendrimer-based nanother-apeutic platform. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1, 502 (2009).
161. A. R. Menjoge, R. M. Kannan, and D. A. Tomalia, Dendrimer-based drug and imaging conjugates: Design considerations for nanomedical applications. Drug Discover. Today 15, 171 (2010).
162. V. Gajbhiye, V. K. Palanirajan, R. K. Tekade, and N. K. Jain, Dendrimers as therapeutic agents: A systematic review. J. Pharm. Pharmacol. 61, 989 (2009).
163. D. Bhadra, S. Bhadra, S. Jain, and N. K. Jain, A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 257, 111 (2003).
164. Y. Cheng, Z. Xu, M. Ma, and T. Xu, Dendrimers as drug carriers: Applications in different routes of drug administration. J. Pharm. Sci. 97, 123 (2008).
165. D. S. Goldberg, H. Ghandehari, and P. W. Swaan, Cellular entry of G3.5 poly (amido amine) dendrimers by clathrin-and dynamin-dependent endocytosis promotes tight junctional opening in intestinal epithelia. Pharm. Res. 27, 1547 (2010).
166. Q. Xu, C. H. Wang, and D. W. Pack, Polymeric carriers for gene delivery: Chitosan and poly(amidoamine) dendrimers. Curr. Pharm. Des. 16, 2350 (2010).
167. I. J. Majoros, T. P. Thomas, C. B. Mehta, and J. R. Baker, Jr., Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J. Med. Chem. 48, 5892 (2005).
168. J. F. Kukowska-Latallo, K. A. Candido, Z. Cao, S. S. Nigavekar, I. J. Majoros, T. P. Thomas, L. P. Balogh, M. K. Khan, and J. R. Baker, Jr., Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65, 5317 (2005).
169. A. Filipowicz and S. Wolowiec, Solubility and in vitro transder-mal diffusion of riboflavin assisted by PAMAM dendrimers. Int. J. Pharm. 408, 152 (2011).
170. R. Wiwattanapatapee, B. Carreno-Gomez, N. Malik, and R. Duncan, Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: A potential oral delivery system?. Pharm. Res. 17, 991 (2000).
171. S. Sadekar and H. Ghandehari, Transepithelial transport and tox-icity of PAMAM dendrimers: Implications for oral drug delivery. Adv. Drug Deliver. Rev. 64, 571 (2012).
172. A. R. Menjoge, A. L. Rinderknecht, R. S. Navath, M. Faridnia, C. J. Kim, R. Romero, R. K. Miller, and R. M. Kannan, Transfer of PAMAM dendrimers across human placenta: Prospects of its use as drug carrier during pregnancy. J. Control Release 150, 326 (2011).
173. S. Beg, A. Samad, M. Alam, and I. Nazish, Dendrimers as novel systems for delivery of neuropharmaceuticals to the brain. CNS Neurol. Disord-Dr. 10, 576 (2011).
174. H. He, Y. Li, X. R. Jia, J. Du, X. Ying, W. L. Lu, J. N. Lou, and Y. Wei, PEGylated poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 32, 478 (2011).
175. W. Ke, K. Shao, R. Huang, L. Han, Y. Liu, J. Li, Y. Kuang, L. Ye, J. Lou, and C. Jiang, Gene delivery targeted to the brain using an angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30, 6976 (2009).
176. J. Sebestik, P. Niederhafner, and J. Jezek, Peptide and glycopeptide dendrimers and analogous dendrimeric structures and their biomed-ical applications. Amino Acids 40, 301 (2011).
177. Y. Li, Y. Cheng, and T. Xu, Design, synthesis and potent pharmaceutical applications of glycodendrimers: A mini review. Curr. Drug Discov. Technol. 4, 246 (2007).
178. J. M. Frechet, Dendrimers and supramolecular chemistry. P. Natl. Acad. Sci. USA. 99, 4782 (2002).
179. Y. Jin, X. Ren, W. Wang, L. Ke, E. Ning, L. Du, and J. Bradshaw, A 5-fluorouracil-loaded pH-responsive dendrimer nanocarrier for tumor targeting. Int. J. Pharm. 420, 378 (2011).
180. K. R. Raghupathi, M. A. Azagarsamy, and S. Thayumanavan, Guest-release control in enzyme-sensitive, amphiphilic-dendrimerbased nanoparticles through photochemical crosslinking. Chem-Eur. J. 17, 11752 (2011).
181. C. C. Lee, E. R. Gillies, M. E. Fox, S. J. Guillaudeu, J. M. Frechet, E. E. Dy, and F. C. Szoka, A single dose of doxorubicinfunctionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. P. Natl. Acad. Sci. USA. 103, 16649 (2006).
182. S. H. Medina and M. E. El-Sayed, Dendrimers as carriers for delivery of chemotherapeutic agents. Chem. Rev. 109, 3141 (2009).
183. M. Longmire, P. L. Choyke, and H. Kobayashi, Dendrimer-based contrast agents for molecular imaging. Curr. Top. Med. Chem. 8, 1180 (2008).
184. M. Jelinkova, J. Strohalm, T. Etrych, K. Ulbrich, and B. Rihova, Starlike versus classic macromolecular prodrugs: Two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs. Pharm. Res. 20, 1558 (2003).
185. J. J. Khandare, S. Jayant, A. Singh, P. Chandna, Y. Wang, N. Vorsa, and T. Minko, Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjugate Chem. 17, 1464 (2006).
186. Y. Cheng, L. Zhao, Y. Li, and T. Xu, Design of biocompatible dendrimers for cancer diagnosis and therapy: Current status and future perspectives. Chem. Soc. Rev. 40, 2673 (2011).
187. D. S. Goldberg, N. Vijayalakshmi, P. W. Swaan, and H. Ghandehari, G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. J. Control Release 150, 318 (2011).
188. S. P. Mukherjee, F. M. Lyng, A. Garcia, M. Davoren, and H. J. Byrne, Mechanistic studies of in vitro cytotoxicity of poly(amidoamine) dendrimers in mammalian cells. Toxicol. Appl. Pharm. 248, 259 (2010).
189. K. Greish, G. Thiagarajan, H. Herd, R. Price, H. Bauer, D. Hubbard, A. Burckle, S. Sadekar, T. Yu, A. Anwar, A. Ray, and H. Ghandehari, Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles. Nanotoxicology 6, 713 (2012).
190. B. Ziemba, A. Janaszewska, K. Ciepluch, M. Krotewicz, W. A. Fogel, D. Appelhans, B. Voit, M. Bryszewska, and B. Klajnert, In vivo toxicity of poly(propyleneimine) dendrimers. J. Biomed. Mater. Res. A 99, 261 (2011).
191. A. M. Chen, M. Zhang, D. Wei, D. Stueber, O. Taratula, T. Minko, and H. He, Co-delivery of doxorubicin and Bcl-2 siRNA by meso-porous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 5, 2673 (2009).
192. F. Dilnawaz, A. Singh, C. Mohanty, and S. K. Sahoo, Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31, 3694 (2010).
193. A. Singh, F. Dilnawaz, S. Mewar, U. Sharma, N. Jagannathan, and S. Sahoo, Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and hydrophilic anticancer drugs and MRI imaging for cancer therapy. ACS Appl. Mater. Interfaces 3, 842 (2011).
194. O. Taratula, A. Kuzmov, M. Shah, O. B. Garbuzenko, and T. Minko, Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control Release 171, 349 (2013).
195. Y. H. Yu, E. Kim, D. E. Park, G. Shim, S. Lee, Y. B. Kim, C. W. Kim, and Y. K. Oh, Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur. J. Pharm. Biopharm. 80, 268 (2012).
196. D. W. Bartlett, H. Su, I. J. Hildebrandt, W. A. Weber, and M. E. Davis, Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. P. Natl. Acad. Sci. USA. 104, 15549 (2007).
197. K. F. Pirollo and E. H. Chang, Does a targeting ligand influence nanoparticle tumor localization or uptake?. Trends Biotechnol. 26, 552 (2008).
198. O. C. Farokhzad and R. Langer, Impact of nanotechnology on drug delivery. ACS Nano 3, 16 (2009).
199. R. Gabathuler, Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 37, 48 (2010).
200. F. Gu, L. Zhang, B. A. Teply, N. Mann, A. Wang, A. F. Radovic-Moreno, R. Langer, and O. C. Farokhzad, Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. P. Natl. Acad. Sci. USA. 105, 2586 (2008).
201. T. M. Allen and P. R. Cullis, Drug delivery systems: Entering the mainstream. Science 303, 1818 (2004).
202. H. Jung, T. Yang, M. D. Lasagna, J. Shi, G. D. Reinhart, and P. S. Cremer, Impact of hapten presentation on antibody binding at lipid membrane interfaces. Biophys. J. 94, 3094 (2008).
203. M. K. Yu, J. Park, and S. Jon, Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2, 3 (2012).
204. N. Ferrara, VEGF as a therapeutic target in cancer. Oncology 69(Suppl 3), 11 (2005).
205. E. Van Cutsem, C. H. Kohne, E. Hitre, J. Zaluski, C. R. Chang Chien, A. Makhson, G. D'Haens, T. Pinter, R. Lim, G. Bodoky, J. K. Roh, G. Folprecht, P. Ruff, C. Stroh, S. Tejpar, M. Schlichting, J. Nippgen, and P. Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408 (2009).
206. Y. Mi, J. Zhao, and S. S. Feng, Targeted co-delivery of doc-etaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin pro-drug nanoparticles for multimodality treatment of cancer. J. Control Release 169, 185 (2013).
207. C. G. Hadjipanayis, R. Machaidze, M. Kaluzova, L. Wang, A. J. Schuette, H. Chen, X. Wu, and H. Mao, EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 70, 6303 (2010).
208. X. Gao, Y. Cui, R. M. Levenson, L. W. Chung, and S. Nie, In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22, 969 (2004).
209. R. Raghavan, M. L. Brady, M. I. Rodriguez-Ponce, A. Hartlep, C. Pedain, and J. H. Sampson, Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg. Focus. 20, E12 (2006).
210. R. H. Bobo, D. W. Laske, A. Akbasak, P. F. Morrison, R. L. Dedrick, and E. H. Oldfield, Convection-enhanced delivery of macromolecules in the brain. P. Natl. Acad. Sci. USA. 91, 2076 (1994).
211. C. G. Hadjipanayis, W. Fellows-Mayle, and N. A. Deluca, Therapeutic efficacy of a herpes simplex virus with radiation or temo-zolomide for intracranial glioblastoma after convection-enhanced delivery. Mol. Ther. 16, 1783 (2008).
212. P. F. Morrison, D. W. Laske, H. Bobo, E. H. Oldfield, and R. L. Dedrick, High-flow microinfusion: Tissue penetration and pharma-codynamics. Am. J. Physiol. 266, R292 (1994).
213. Y. Ling, K. Wei, Y. Luo, X. Gao, and S. Zhong, Dual doc-etaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. Bioma-terials 32, 7139 (2011).
214. M. Wente, A. Jain, E. Kono, P. Berberat, T. Giese, H. Reber, H. Friess, M. Büchler, R. Reiter, and O. Hines, Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas 31, 119 (2005).
215. G. Chen, W. Chen, Z. Wu, R. Yuan, H. Li, J. Gao, and X. Shuai, MRI-visible polymeric vector bearing CD3 single chain antibody for gene delivery to T cells for immunosuppression. Biomaterials 30, 1962 (2009).
216. U. I. Tromsdorf, N. C. Bigall, M. G. Kaul, O. T. Bruns, M. S. Nikolic, B. Mollwitz, R. A. Sperling, R. Reimer, H. Hohenberg, W. J. Parak, S. Forster, U. Beisiegel, G. Adam, and H. Weller, Size and surface effects on the MRI relaxivity of manganese ferrite nanoparticle contrast agents. Nano Lett. 7, 2422 (2007).
217. B. A. Olenchock, R. Guo, J. H. Carpenter, M. Jordan, M. K. Topham, G. A. Koretzky, and X. P. Zhong, Disruption of diacyl-glycerol metabolism impairs the induction of T cell anergy. Nat. Immunol. 7, 1174 (2006).
218. X. P. Zhong, E. A. Hainey, B. A. Olenchock, H. Zhao, M. K. Topham, and G. A. Koretzky, Regulation of T cell receptor-induced activation of the Ras-ERK pathway by diacylglycerol kinase zeta. J. Biol. Chem. 277, 31089 (2002).
219. R. M. Lu, Y. L. Chang, M. S. Chen, and H. C. Wu, Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 32, 3265 (2011).
220. C. Birchmeier, W. Birchmeier, E. Gherardi, and G. F. Vande Woude, Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915 (2003).
221. F. Cappuzzo, A. Marchetti, M. Skokan, E. Rossi, S. Gajapathy, L. Felicioni, M. Del Grammastro, M. G. Sciarrotta, F. Buttitta, M. Incarbone, L. Toschi, G. Finocchiaro, A. Destro, L. Terracciano, M. Roncalli, M. Alloisio, A. Santoro, and M. Varella-Garcia, Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 27, 1667 (2009).
222. S. Ding, T. Merkulova-Rainon, Z. C. Han, and G. Tobelem, HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 101, 4816 (2003).
223. A. Z. Wang, F. Gu, L. Zhang, J. M. Chan, A. Radovic-Moreno, M. R. Shaikh, and O. C. Farokhzad, Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin. Biol. Th. 8, 1063 (2008).
224. J. R. McCarthy, J. Bhaumik, M. R. Karver, S. S. Erdem, and R. Weissleder, Targeted nanoagents for the detection of cancers. Mol. Oncol. 4, 511 (2010).
225. M. Kumar, M. Yigit, G. Dai, A. Moore, and Z. Medarova, Image-guided breast tumor therapy using a small interfering RNA nan-odrug. Cancer Res. 70, 7553 (2010).
226. L. Perey, D. F. Hayes, P. Maimonis, M. Abe, C. O'Hara, and D. W. Kufe, Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res. 52, 2563 (1992).
227. D. Liu, L. M. Bimbo, E. Makila, F. Villanova, M. Kaasalainen, B. Herranz-Blanco, C. M. Caramella, V. P. Lehto, J. Salonen, K. H. Herzig, J. Hirvonen, and H. A. Santos, Co-delivery of a hydropho-bic small molecule and a hydrophilic peptide by porous silicon nanoparticles. J. Control Release 170, 268 (2013).
228. X. Li, X. Lu, H. Xu, Z. Zhu, H. Yin, X. Qian, R. Li, X. Jiang, and B. Liu, Paclitaxel/tetrandrine coloaded nanoparticles effectively promote the apoptosis of gastric cancer cells based on oxidation therapy. Mol. Pharm. 9, 222 (2012).
229. H. Mok, J. W. Park, and T. G. Park, Enhanced intracellular delivery of quantum dot and adenovirus nanoparticles triggered by acidic pH via surface charge reversal. Bioconjugate Chem. 19, 797 (2008).
230. K. H. Min, J. H. Kim, S. M. Bae, H. Shin, M. S. Kim, S. Park, H. Lee, R. W. Park, I. S. Kim, K. Kim, I. C. Kwon, S. Y. Jeong, and D. S. Lee, Tumoral acidic pH-responsive MPEG-poly(beta-amino ester) polymeric micelles for cancer targeting therapy. J. Control Release 144, 259 (2010).
231. V. A. Sethuraman, K. Na, and Y. H. Bae, pH-responsive sulfon-amide/PEI system for tumor specific gene delivery: An in vitro study. Biomacromolecules 7, 64 (2006).
232. H. Mok, O. Veiseh, C. Fang, F. M. Kievit, F. Y. Wang, J. O. Park, and M. Zhang, pH-Sensitive siRNA nanovector for targeted gene silencing and cytotoxic effect in cancer cells. Mol. Pharm. 7, 1930 (2010).
233. Y. Lee, S. Fukushima, Y. Bae, S. Hiki, T. Ishii, and K. Kataoka, A protein nanocarrier from charge-conversion polymer in response to endosomal pH. J. Am. Chem. Soc. 129, 5362 (2007).
234. D. Simberg, T. Duza, J. H. Park, M. Essler, J. Pilch, L. Zhang, A. M. Derfus, M. Yang, R. M. Hoffman, S. Bhatia, M. J. Sailor, and E. Ruoslahti, Biomimetic amplification of nanoparticle homing to tumors. P. Natl. Acad. Sci. USA. 104, 932 (2007).
235. E. A. Perez, Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res. Tr. 114, 195 (2009).
236. H. Zhang, Y. Ma, and X. L. Sun, Recent developments in carbohydrate-decorated targeted drug/gene delivery. Med. Res. Rev. 30, 270 (2010).
237. Z. Shen, W. Wei, H. Tanaka, K. Kohama, G. Ma, T. Dobashi, Y. Maki, H. Wang, J. Bi, and S. Dai, A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy. Pharmacol. Res. 64, 410 (2011).
238. E. M. Kim, H. J. Jeong, I. K. Park, C. S. Cho, H. B. Moon, D. Y. Yu, H. S. Bom, M. H. Sohn, and I. J. Oh, Asialoglycoprotein receptor targeted gene delivery using galactosylated polyethylenimine-graft-poly(ethylene glycol): In vitro and in vivo studies. J. Control Release 108, 557 (2005).
239. Y. Yang, Z. Zhang, L. Chen, W. Gu, and Y. Li, Galactosy-lated poly(2-(2-aminoethyoxy)ethoxy)phosphazene/DNA complex nanoparticles: In vitro and in vivo evaluation for gene delivery. Biomacromolecules 11, 927 (2010).
240. H. L. Jiang, J. T. Kwon, E. M. Kim, Y. K. Kim, R. Arote, D. Jere, H. J. Jeong, M. K. Jang, J. W. Nah, C. X. Xu, I. K. Park, M. H. Cho, and C. S. Cho, Galactosylated poly(ethylene glycol)-chitosan-graft-polyethylenimine as a gene carrier for hepatocyte-targeting. J. Control Release 131, 150 (2008).
241. W. Lu, C. Xiong, G. Zhang, Q. Huang, R. Zhang, J. Z. Zhang, and C. Li, Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres. Clin. Cancer Res. 15, 876 (2009).
242. A. B. Foraker, C. M. Khantwal, and P. W. Swaan, Current perspectives on the cellular uptake and trafficking of riboflavin. Adv. Drug Deliver. Rev. 55, 1467 (2003).
243. A. A. Karande, L. Sridhar, K. S. Gopinath, and P. R. Adiga, Riboflavin carrier protein: A serum and tissue marker for breast carcinoma. Int. J. Cancer 95, 277 (2001).
244. J. Jayapaul, M. Hodenius, S. Arns, W. Lederle, T. Lammers, P. Comba, F. Kiessling, and J. Gaetjens, FMN-coated fluorescent iron oxide nanoparticles for RCP-mediated targeting and labeling of metabolically active cancer and endothelial cells. Biomaterials 32, 5863 (2011).
245. C. M. Lee, H. J. Jeong, E. M. Kim, D. W. Kim, S. T. Lim, H. T. Kim, I. K. Park, Y. Y. Jeong, J. W. Kim, and M. H. Sohn, Super-paramagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocytes in vivo. Magn. Reson. Med. 62, 1440 (2009).
246. D. S. Wilson and J. W. Szostak, In vitro selection of functional nucleic acids. Annu. Rev. Biochem. 68, 611 (1999).
247. C. Tuerk and L. Gold, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA poly-merase. Science 249, 505 (1990).
248. B. Liu, J. N. Zhang, J. Liao, J. Liu, K. Chen, G. X. Tong, P. Yuan, Z. X. Liu, Y. Pu, and H. X. Liu, Aptamer-functionalized nanopar-ticles for drug delivery. J. Biomed. Nanotechnol. 10, 3189 (2014).
249. Z. J. Xi, R. R. Huang, Y. Deng, and N. Y. He, Progress in selection and biomedical applications of aptamers. J. Biomed. Nanotechnol. 10, 3043 (2014).
250. A. Aravind, S. Varghese, S. Veeranarayanan, A. Mathew, Y. Nagaoka, S. Iwai, T. Fukuda, T. Hasumura, Y. Yoshida, T. Maekawa, and D. S. Kumar, Aptamer-labeled PLGA nanoparti-cles for targeting cancer cells. Cancer Nanotechnol. 3, 1 (2012).
251. J. F. Lee, J. R. Hesselberth, L. A. Meyers, and A. D. Ellington, Aptamer database. Nucleic Acids Res. 32, D95 (2004).
252. J. F. Lee, G. M. Stovall, and A. D. Ellington, Aptamer therapeutics advance. Curr. Opin. Chem. Biol. 10, 282 (2006).
253. J. E. Rosenberg, R. M. Bambury, E. M. Van Allen, H. A. Drabkin, P. N. Lara, Jr., A. L. Harzstark, N. Wagle, R. A. Figlin, G. W. Smith, L. A. Garraway, T. Choueiri, F. Erlandsson, and D. A. Laber, A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest. Invest. New Drug. 32, 178 (2014).
254. P. J. Bates, J. B. Kahlon, S. D. Thomas, J. O. Trent, and D. M. Miller, Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J. Biol. Chem. 274, 26369 (1999).
255. P. J. Bates, D. A. Laber, D. M. Miller, S. D. Thomas, and J. O. Trent, Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 86, 151 (2009).
256. F. Mongelard and P. Bouvet, AS-1411, a guanosine-rich oligonu-cleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr. Opin. Mol. Ther. 12, 107 (2010).
257. P. R. Bouchard, R. M. Hutabarat, and K. M. Thompson, Discovery and development of therapeutic aptamers. Annu. Rev. Pharmacol. 50, 237 (2010).
258. S. E. Lupold, B. J. Hicke, Y. Lin, and D. S. Coffey, Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62, 4029 (2002).
259. V. Bagalkot, O. C. Farokhzad, R. Langer, and S. Jon, An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl. 45, 8149 (2006).
260. O. C. Farokhzad, J. Cheng, B. A. Teply, I. Sherifi, S. Jon, P. W. Kantoff, J. P. Richie, and R. Langer, Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. P. Natl. Acad. Sci. USA. 103, 6315 (2006).
261. O. C. Farokhzad, S. Jon, A. Khademhosseini, T. N. Tran, D. A. Lavan, and R. Langer, Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res. 64, 7668 (2004).
262. J. P. Dassie, X. Y. Liu, G. S. Thomas, R. M. Whitaker, K. W. Thiel, K. R. Stockdale, D. K. Meyerholz, A. P. McCaffrey, J. O. McNamara, 2nd, and P. H. Giangrande, Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 27, 839 (2009).
263. W. Hwang do, H. Y. Ko, J. H. Lee, H. Kang, S. H. Ryu, I. C. Song, D. S. Lee, and S. Kim, A nucleolin-targeted multimodal nanopar-ticle imaging probe for tracking cancer cells using an aptamer. J. Nucl. Med. 51, 98 (2010).
264. M. Derenzini, V. Sirri, D. Trere, and R. L. Ochs, The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Lab. Invest. 73, 497 (1995).
265. P. Antunes, M. Ginj, H. Zhang, B. Waser, R. P. Baum, J. C. Reubi, and H. Maecke, Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur. J. Nucl. Med. Mol. I. 34, 982 (2007).
266. N. Li, T. Larson, H. H. Nguyen, K. V. Sokolov, and A. D. Ellington, Directed evolution of gold nanoparticle delivery to cells. Chem. Commun. 46, 392 (2010).
267. U. Gunthert, M. Hofmann, W. Rudy, S. Reber, M. Zoller, I. Haussmann, S. Matzku, A. Wenzel, H. Ponta, and P. Herrlich, A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65, 13 (1991).
268. V. M. Platt and F. C. Szoka, Jr., Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharm. 5, 474 (2008).
269. S. H. Bhang, N. Won, T. J. Lee, H. Jin, J. Nam, J. Park, H. Chung, H. S. Park, Y. E. Sung, S. K. Hahn, B. S. Kim, and S. Kim, Hyaluronic acid-quantum dot conjugates for in vivo lymphatic vessel imaging. ACS Nano 3, 1389 (2009).
270. W. Wu, J. Shen, P. Banerjee, and S. Zhou, Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal treatment. Biomaterials 31, 7555 (2010).
271. A. M. Pekkanen, M. R. DeWitt, and M. N. Rylander, Nanoparticle enhanced optical imaging and phototherapy of cancer. J. Biomed. Nanotechnol. 10, 1677 (2014).
272. D. Yoo, J. H. Lee, T. H. Shin, and J. Cheon, Theranostic magnetic nanoparticles. Accounts Chem. Res. 44, 863 (2011).
273. J. E. Rosen, L. Chan, D. B. Shieh, and F. X. Gu, Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomedicine-UK. 8, 275 (2012).
274. R. Singh and H. S. Nalwa, Medical applications of nanoparticles in biological imaging, cell labeling, antimicrobial agents, and anti-cancer nanodrugs. J. Biomed. Nanotechnol. 7, 489 (2011).
275. F. X. Gu, R. Karnik, A. Z. Wang, F. Alexis, E. Levy-Nissenbaum, S. Hong, R. S. Langer, and O. C. Farokhzad, Targeted nanoparticles for cancer therapy. Nano Today 2, 14 (2007).
276. M. Nurunnabi, Z. Khatun, W.-C. Moon, G. Lee, and Y.-K. Lee, Heparin based nanoparticles for cancer targeting and noninvasive imaging. Quant. Imaging Med. Surg. 2, 219 (2012).
277. W. B. Cai and X. Y. Chen, Nanoplatforms for targeted molecular imaging in living subjects. Small 3, 1840 (2007).
278. C. Khemtong, C. W. Kessinger, and J. Gao, Polymeric nanomedicine for cancer MR imaging and drug delivery. Chem. Commun. 3497 (2009).
279. S. Gelperina, K. Kisich, M. D. Iseman, and L. Heifets, The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am. J. Resp. Crit. Care. 172, 1487 (2005).
280. J. H. Park, G. Saravanakumar, K. Kim, and I. C. Kwon, Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv. Drug Deliver. Rev. 62, 28 (2010).
281. N. Ahmed, H. Fessi, and A. Elaissari, Theranostic applications of nanoparticles in cancer. Drug Discov. Today 17, 928 (2012).
282. S. S. Kelkar and T. M. Reineke, Theranostics: Combining imaging and therapy. Bioconjugate Chem. 22, 1879 (2011).
283. K. Kim, J. H. Kim, H. Park, Y. S. Kim, K. Park, H. Nam, S. Lee, J. H. Park, R. W. Park, I. S. Kim, K. Choi, S. Y. Kim, K. Park, and I. C. Kwon, Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J. Control Release 146, 219 (2010).
284. K. H. Min, K. Park, Y. S. Kim, S. M. Bae, S. Lee, H. G. Jo, R. W. Park, I. S. Kim, S. Y. Jeong, K. Kim, and I. C. Kwon, Hydropho-bically modified glycol chitosan nanoparticles-encapsulated camp-tothecin enhance the drug stability and tumor targeting in cancer therapy. J. Control Release 127, 208 (2008).
285. J. H. Na, H. Koo, S. Lee, K. H. Min, K. Park, H. Yoo, S. H. Lee, J. H. Park, I. C. Kwon, S. Y. Jeong, and K. Kim, Real-time and non-invasive optical imaging of tumor-targeting glycol chi-tosan nanoparticles in various tumor models. Biomaterials 32, 5252 (2011).
286. J. H. Ryu, S. A. Kim, H. Koo, J. Y. Yhee, A. Lee, J. H. Na, I. Youn, K. Choi, I. C. Kwon, B.-S. Kim, and K. Kim, Cathepsin B-sensitive nanoprobe for in vivo tumor diagnosis. J. Mater. Chem. 21, 17631 (2011).
287. K. J. Chen, Y. L. Chiu, Y. M. Chen, Y. C. Ho, and H. W. Sung, Intracellularly monitoring/imaging the release of doxorubicin from pH-responsive nanoparticles using Forster resonance energy transfer. Biomaterials 32, 2586 (2011).
288. H. Kobayashi and P. L. Choyke, Target-cancer-cell-specific acti-vatable fluorescence imaging probes: Rational design and in vivo applications. Accounts Chem. Res. 44, 83 (2011).
289. M. J. Pittet and R. Weissleder, Intravital imaging. Cell 147, 983 (2011).
290. A. Bullen, Microscopic imaging techniques for drug discovery. Nat. Rev. Drug Discov. 7, 54 (2008).
291. P. Amornphimoltham, A. Masedunskas, and R. Weigert, Intravital microscopy as a tool to study drug delivery in preclinical studies. Adv. Drug Deliver. Rev. 63, 119 (2011).
292. M. E. Eichhorn, S. Strieth, S. Luedemann, A. Kleespies, U. Noth, A. Passon, G. Brix, K. W. Jauch, C. J. Bruns, and M. Dellian, Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment. Cancer Biol. Ther. 7, 1006 (2008).
293. H. Cabral, Y. Matsumoto, K. Mizuno, Q. Chen, M. Murakami, M. Kimura, Y. Terada, M. R. Kano, K. Miyazono, M. Uesaka, N. Nishiyama, and K. Kataoka, Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6, 815 (2011).